The DOI matches its Crossref record.
Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA)
Abstract
3007 Background: CD137 is a member of the TNFR family and functions as a costimulatory molecule. In preclinical studies BMS- 663513, a fully human anti-CD137 agonist monoclonal antibody provided costimulation to CD8+ and CD4+ T-cells, leading to enhanced IFNγ production, cytolytic activity, and increased survival. We conducted a first-in-human phase I dose-escalation study of BMS-663513 in pts with CA. Methods: BMS-663513 was administered IV every 3 weeks. In Part 1, the dose was escalated (0.3, 1, 3, 6, 10, and 15 mg/kg) in cohorts of 3–6 pts. In Part 2, pts with melanoma, RCC, and ovarian CA, 30 per CA, were stratified by tumor type and randomized to receive 1, 3, and 10 mg/kg dose levels. Tumor response (modified WHO) was determined after the 4th dose and then every 2 doses. After 4 doses, treatment continued in pts with antitumor activity and without dose-limiting toxicity (DLT). Tumor biopsies were obtained from pts in Part 1 pretreatment and during cycle 2; PBMC, serum, and plasma were also obtained from all pts at select times for exploratory biomarker analysis. Results: 83 pts (54 melanoma, 15 RCC, 13 ovarian and 1 prostate) have been treated. Part 2 melanoma enrollment is complete. In Part 1, single DLTs were reported in the 0.3 mg/kg (Gr 3 neutropenia), and 15 mg/kg (Gr 4 neutropenia) cohorts. Overall, fatigue (All, 26%, Gr 3–4, 3%), reversible Gr 3–4 transaminitis (11%) and Gr 3–4 neutropenia (5%) were the most common agent-related AEs. 3 PRs (18+ mo, 3+ mo, 1.5+ mo, all melanoma) and 4 SD (10 mo, 6 mo, 6 mo, 4+ mo) occurred at all three doses tested in expansion cohorts. Preliminary biomarker analysis demonstrated increased expression of IFN-inducible genes in peripheral blood, serum neopterin levels, and percentage of circulating activated (HLA-DR+, CD69+) CD8 and CD4 T-cells following a single treatment. Increased expression of CD8a and IFNγ were detected in post- treatment biopsies in a subset of pts. Conclusions: BMS-663513 was tolerable across a wide dose range (0.3–15 mg/kg). As a single agent, BMS-663513 demonstrates clinical activity that justifies its further evaluation both as a single agent and in combination with other treatment modalities. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Bristol-Myers Squibb Bristol-Myers Squibb Bristol-Myers Squibb
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Coinhibitory Pathways in Immunotherapy for Cancer
Baumeister, S. H., Freeman, G. J., Dranoff, G., & Sharpe, A. H. (2016) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112049 · Cited by 910
Stagg, J., Loi, S., Divisekera, U., Ngiow, S. F., Duret, H., Yagita, H., Teng, M. W., & Smyth, M. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016569108 · Cited by 496
OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer Patients
Curti, B. D., Kovacsovics-Bankowski, M., Morris, N., Walker, E., Chisholm, L., Floyd, K., Walker, J., Gonzalez, I., Meeuwsen, T., Fox, B. A., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4174 · Cited by 496
Clinical targeting of the TNF and TNFR superfamilies
Croft, M., Benedict, C. A., & Ware, C. F. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3930 · Cited by 456
Immunotherapy of cancer in 2012
Kirkwood, J. M., Butterfield, L. H., Tarhini, A. A., Zarour, H., Kalinski, P., & Ferrone, S. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20132 · Cited by 436
Self-citation
Metadata
- Authors
- Sznol, M., Hodi, F. S., Margolin, K., McDermott, D. F., Ernstoff, M. S., Kirkwood, J. M., Wojtaszek, C., Feltquate, D., & Logan, T.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-05-20
- Volume
- 26
- Issue
- 15_suppl
- Pages
- 3007-3007
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2136364651
- Cited by
- 204
- References
- 0
- Type
- conference abstract
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA). https://app.cochat.ai/papers/10.1200/jco.2008.26.15_suppl.3007
- The paper
- Sznol, M., Hodi, F. S., Margolin, K., McDermott, D. F., Ernstoff, M. S., Kirkwood, J. M., Wojtaszek, C., Feltquate, D., & Logan, T. (2008). Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA). Journal of Clinical Oncology. https://doi.org/10.1200/jco.2008.26.15_suppl.3007
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.